1. Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group12. Issue 7 (13th July 2012) Authors: Gilbert, Jill; Lee, Ju Whei; Argiris, Athanassios; Haigentz, Missak; Feldman, Lawrence Eric; Jang, Minyoung; Arun, Pattatheyil; Van Waes, Carter; Forastiere, Arlene A. Journal: Head & neck Issue: Volume 35:Issue 7(2013:Jul.) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗